Golden Hour Intravenous Thrombolysis for Acute Ischemic Stroke: A Systematic Review and Meta‐Analysis

Objectives The benefits of intravenous thrombolysis are time‐dependent, with maximum efficacy when administered within the first “golden” hour after onset. Nevertheless, the impact of golden hour thrombolysis has not been well quantified. Methods Medline, Embase, and Web of Science databases were systematically searched from inception to August 27, 2023. We included studies that reported safety and efficacy outcomes of ischemic stroke patients treated with intravenous thrombolysis in the golden hour versus later treatment window. The primary outcome was an excellent functional outcome, defined as a modified Rankin Scale score of 0–1 at 90 days. The secondary efficacy outcome was a good functional outcome (defined as modified Rankin Scale score of 0–2). The main safety outcome was symptomatic intracerebral hemorrhage. Results Seven studies involving 78,826 patients met the selection criteria. Golden hour thrombolysis was associated with higher odds of 90‐day excellent functional outcomes (OR 1.40, 95% CI 1.16–1.67) and 90‐day good functional outcomes (OR 1.38, 95% CI 1.13–1.69) compared with thrombolysis outside the golden hour. The number needed to treat to benefit for golden hour thrombolysis to reduce disability by at least 1 level on the modified Rankin Scale per patient was 2.6. Rates of symptomatic intracerebral hemorrhage and mortality were similar between groups. Interpretation Golden hour thrombolysis significantly improved acute ischemic stroke outcomes. The findings provide rationale for intensive efforts aimed at expediting thrombolytic therapy within the golden hour window following the onset of acute ischemic stroke. ANN NEUROL 2024